T-cell activation in ischemic stroke: a new therapeutic target for delayed infarct expansion?
Lin
Ning
N
Friedlander
Robert M
RM
D000818:Animals; D020520:Brain Infarction / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology / Q000628:therapy*; D016207:Cytokines / Q000235:genetics / Q000378:metabolism; D004195:Disease Models, Animal; D000068876:Fingolimod Hydrochloride; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D020244:Infarction, Middle Cerebral Artery / Q000150:complications* / Q000276:immunology*; D020381:Interleukin-17 / Q000172:deficiency; D053759:Interleukin-23 / Q000172:deficiency; D051379:Mice; D018345:Mice, Knockout; D011409:Propylene Glycols / Q000627:therapeutic use; D013110:Sphingosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology*
D016207:Cytokines; D007166:Immunosuppressive Agents; D020381:Interleukin-17; D053759:Interleukin-23; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine